

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Aflibercept

Initial application — diabetic macular oedema

Applications from any relevant practitioner. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has centre involving diabetic macular oedema (DMO)
- and
- ☐ Patient's disease is non responsive to 4 doses of intravitreal bevacizumab when administered 4-6 weekly
- and
- ☐ Patient has reduced visual acuity between 6/9 – 6/36 with functional awareness of reduction in vision
- and
- ☐ Patient has DMO within central OCT (ocular coherence tomography) subfield > 350 micrometers
- and
- ☐ There is no centre-involving sub-retinal fibrosis or foveal atrophy
- and
- ☐ Patient has not previously been treated with faricimab for longer than 3 months

Renewal — diabetic macular oedema

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 12 months.

Prerequisites(tick boxes where appropriate)

- ☐ There is stability or two lines of Snellen visual acuity gain
- and
- ☐ There is structural improvement on OCT scan (with reduction in intra-retinal cysts, central retinal thickness, and sub-retinal fluid)
- and
- ☐ Patient's vision is 6/36 or better on the Snellen visual acuity score
- and
- ☐ There is no centre-involving sub-retinal fibrosis or foveal atrophy

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
.....		

Aflibercept - continued

Initial application — wet age related macular degeneration

Applications from any relevant practitioner. Approvals valid for 3 months.

Prerequisites(tick boxes where appropriate)

- ☐ Wet age-related macular degeneration (wet AMD)
or
☐ Polypoidal choroidal vasculopathy
or
☐ Choroidal neovascular membrane from causes other than wet AMD

and

- ☐ The patient has developed severe endophthalmitis or severe posterior uveitis following treatment with bevacizumab
or
☐ There is worsening of vision or failure of retina to dry despite three intraocular injections of bevacizumab four weeks apart

and

- ☐ There is no structural damage to the central fovea of the treated eye
and
☐ Patient has not previously been treated with ranibizumab or faricimab for longer than 3 months

or

- ☐ Patient has current approval to use ranibizumab or faricimab for treatment of wAMD and was found to be intolerant within 3 months
or
☐ Patient has previously* (*before June 2018) received treatment with ranibizumab for wAMD and disease was stable while on treatment

Renewal — wet age related macular degeneration

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 12 months.

Prerequisites(tick boxes where appropriate)

- ☐ Documented benefit must be demonstrated to continue
and
☐ Patient's vision is 6/36 or better on the Snellen visual acuity score
and
☐ There is no structural damage to the central fovea of the treated eye

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz